CURE Childhood Cancer
A Phase I Study of 131I-MIBG with Dinutuximab for Relapsed/Refractory Neuroblastoma
Role: PI
Aflac Cancer & Blood Disorders Center Institutional Research Funds
NANT 2017-01: A Phase I Study of 131I-MIBG with Dinutuximab for Relapsed/Refractory Neuroblastoma
Role: PI
Ignyta/Roche
A Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX-101) in Children and Adolescents with Recurrent or Refractory Solid Tumors and Primary CNS Tumors, with or without TRK, ROS1, or ALK Fusions, 1% effort
Role: Site PI
PI: Ignyta/Roche